



## Appendix 21 - Follicular lymphoma

### Approved settings/ treatment line

Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
<b>1<sup>st</sup> line</b>	Bendamustine + Rituximab or obinutuzumab.		Category 2A, Preferred
	CHOP + Rituximab or obinutuzumab.	cyclophosphamide, doxorubicin, vincristine, prednisone	Category 2A, Preferred
	CVP + Rituximab or obinutuzumab.	cyclophosphamide, vincristine, prednisone	Category 2A, Preferred
	Lenalidomide + Rituximab.		Category 2A, Preferred
	Rituximab.		Category 2A, Low-tumor burden
	Lenalidomide + Obinutuzumab.		Category 2B
<b>1<sup>st</sup> line, Elderly</b>	Rituximab for 4 doses.		Category 2A, Preferred
	Cyclophosphamide ± Rituximab		Category 2A
	Chlorambucil ± Rituximab		Category 2A
<b>1<sup>st</sup> line consolidation (optional)</b>	Rituximab every 8-12 weeks for 12 doses		Category 1, High tumor burden
	Obinutuzumab every 8 weeks for 12 doses.		Category 2A
	Rituximab every 8 weeks for 4 doses		Category 2A, In case of previous use of rituximab as single agent
<b>2<sup>nd</sup> line</b>	Bendamustine + Rituximab or obinutuzumab.		Category 2A, Preferred
	CHOP + Rituximab or obinutuzumab.	cyclophosphamide, doxorubicin, vincristine, prednisone	Category 2A, Preferred
	CVP + Rituximab or obinutuzumab.	cyclophosphamide, vincristine, prednisone	Category 2A, Preferred
	Lenalidomide + Rituximab.		Category 2A, Preferred
	Lenalidomide + Obinutuzumab		Category 2A
	Lenalidomide.		Category 2A, No willing for Anti-CD20
	Obinutuzumab.		Category 2A
	Rituximab.		Category 2A
<b>2<sup>ND</sup> line, Elderly</b>	Rituximab for 4 doses.		Category 2A, Preferred
	Cyclophosphamide ± Rituximab		Category 2A
	Chlorambucil ± Rituximab		Category 2A
<b>2<sup>nd</sup> line Consolidation (optional)</b>	Rituximab every 12 weeks for 2 years		Category 1, Preferred
	Obinutuzumab every 8 weeks for 12 doses		Category 2A



Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
<b>Histological transformation (Transplant candidate)</b>	DHAP ± Rituximab	dexamethasone, cytarabine, cisplatin	Category 2A, Preferred
	DHAX ± Rituximab	dexamethasone, cytarabine, oxaliplatin	Category 2A, Preferred
	GDP ± Rituximab	dexamethasone, cisplatin, gemcitabine	Category 2A, Preferred
	ICE ± Rituximab	Ifosfamide, carboplatin, etoposide	Category 2A, Preferred
	ESHAP ± Rituximab	etoposide, methyl prednisolone, cytarabine, cisplatin	Category 2A
	GemOx ± Rituximab	gemcitabine, oxaliplatin	Category 2A
	MINE ± Rituximab	mitoxantrone, ifosfamide, etoposide, MESNA	Category 2A
<b>Histological transformation (Non-Transplant candidate)</b>	GemOx ± Rituximab	gemcitabine, oxaliplatin	Category 2A, Preferred
	Rituximab.		Category 2A
	Brentuximab-vedotin		Category 2A, CD30 +ve
	Bendamustine ± Rituximab		Category 2B
	Ibrutinib.		Category 2A, non-GCB DLBCL
	Lenalidomide ± Rituximab.		Category 2A, non-GCB DLBCL
	CEPP ± Rituximab	cyclophosphamide, etoposide, procarbazine, prednisone	Category 2A
	CEOP ± Rituximab	Cyclophosphamide, etoposide, vincristine, prednisone	Category 2A
	DA-EPOCH ± Rituximab	Etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide, CSF	Category 2A
	GDP ± Rituximab	dexamethasone, cisplatin, gemcitabine	Category 2A